Gene Therapies For Ocular Disease With Sparing Vision's Stéphane Boissel

We love to hear from our listeners. Send us a message. Since assuming the President and CEO role at Sparingvision in August, 2020, Stéphane Boissel has been making big moves in the arenas of talent acquisition and IP expansion. Those efforts are securing the company's development of a number of genomic medicines to address inherited retinal disease. On this episode of the Business of Biotech, Boissel shares the company's foundation story and the role venture philanthropy pla...